FA
VCYT icon

Friess Associates’s Veracyte VCYT Stock Holding History

Friess Associates’s Portfolio VCYT Stock Details VCYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7,403
Closed -$192K – 139
2020
Q2 		$192K Sell
7,403
-241,760
-97% -$6.02M 0.02% 102
2020
Q1 		$6.06M Buy
+249,163
New +$6.27M 0.6% 53
2019
Q3 		– Sell
-130,856
Closed -$3.73M – 137
2019
Q2 		$3.73M Sell
130,856
-25,550
-16% -$638K 0.27% 91
2019
Q1 		$3.91M Buy
+156,406
New +$2.99M 0.29% 85

Other funds holding VCYT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Friess Associates's VCYT Position: Q3 2020 in Review

Friess Associates sold out of Veracyte (VCYT) in Q3 2020, closing a stake of 7,403 shares — an estimated $192K sold.

Friess Associates first reported a position in VCYT in Q1 2019 and held it in 4 quarters. The position peaked at $6.06M in Q1 2020. 189 funds tracked by Wall St. Rank hold VCYT as of Q3 2020.

  • Friess Associates reported no remaining Veracyte position as of Q3 2020 after selling out during the quarter.
  • Friess Associates sold 7,403 Veracyte shares in Q3 2020, an estimated $192K.
  • Friess Associates first reported a position in Veracyte in Q1 2019 and held it in 4 quarters.
  • Friess Associates's Veracyte position peaked at $6.06M in Q1 2020.
  • 189 funds tracked by Wall St. Rank held Veracyte as of Q3 2020.

Based on Friess Associates's 13F filing for Q3 2020, filed 13 Nov 2020.